scholarly journals Engraftment of unrelated cord blood after reduced-intensity conditioning regimen in children with refractory neuroblastoma: a feasibility trial

2010 ◽  
Vol 46 (2) ◽  
pp. 232-237 ◽  
Author(s):  
C Jubert ◽  
D A Wall ◽  
M Grimley ◽  
M A Champagne ◽  
M Duval
Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3143-3143 ◽  
Author(s):  
Vanderson Rocha ◽  
Bernard Rio ◽  
Federico Garnier ◽  
Marc Renaud ◽  
Anne Sirvent ◽  
...  

Abstract Results of reduced intensity conditioning regimen (RIC) in unrelated cord blood transplantation (UCBT) have been reported, however more frequently RIC was performed using double cord blood transplants. In order to study risk factors in single RIC-UCBT we have analyzed 65 patients with hematological malignancies (ALL=10, AML=37, Hodking and NHL=10, MDS=4, CML=3, Myeloma =1) transplanted from 1999–2005 and reported to Eurocord and SFGM-TC. The median follow-up was 8 months (3–26) and the median age was 47 years (16–76). At transplant, 49% of the patients had advanced phase of disease and 39% had received a previous autologous transplants. The conditioning regimen varied according diasease and centers: Fludarabine(FLU)+Endoxan (EDX) +TBI (2Gy) was given to 33 patients, FLU+(EDX or Melphalan) in 11, FLU+BU (<8mg/kg) associated or not to other drugs in 13, FLU+TBI(2GY) in 3 and other regimens in 5 patients. ATG/ALG was added in 26% of the cases. GVHD prophylaxis most commonly (55%) consisted of CsA and MMF; 87% received hematopoietic growth factors (<day 8). The median nucleated cell dose infused was 2.4 x107/kg and the graft was HLA identical (6/6) ( HLA A and B low resolution and DRB1 allelic typing) in 3 cases, 5/6 in 15, 4/6 in 37 and 3/6 in 10. Results: Median time to neutrophil recovery (>500/mm3) was 20 days (0–56) and 35 dyas for platelets recovery (>20.000/mm3). At day 60 probability of neutrophil recovery was 87± 7% of the 33 patients who received the Flu+End+TBI conditioning regimen and was 65±10% for patients receiving other regimens (p<0.01). Chimerism analysis was available in 71% of the patients at 3 months and was full donor in 67%, mixed chimerism in 9% and autologous reconstitution in 24%. Grade II aGVHD was observed in 13%, grade III in 7% and grade IV in 7%; the TRM was 45±7% overall, 50±15% in acute leukemia, 30±15% in lymphomas and 27±16% for other diagnoses. The TRM at one year for those receiving <2.4 x 107 TNC/kg was 53±9% and for those receiving >2.4 x107TNC/kg was 39±10% (p=0.07). For patients receiving Flu+End+TBI the TRM at one year was 24±10% and for those receiving other conditioning regimens was 60±9% (p=0.001). DFS at one year for lymphomas was 50±9%, for leukemias was 27±7% and for other diagnoses was zero. When the HLA compatibility was 6/6 or 5/6, DFS at one year was 42±12%, for 4/6 disparities DFS was 27±9% and for 3/6 disparities DFS was zero. DFS was 43±11% for those receiving Flu+End+TBI, and was 16±7% for patients receiving other conditioning regimens (p=0.005). For patients receiving >2.4 x 107TNC/kg the DFS was 31±12% and for patients receiving <2.4 x 107TNC/kg the DFS was 14±8% (p=0.05). In collusion, results of single RIC-UCBT are encouraging; cell dose and HLA remain important factors in this setting. The type of conditioning (Flu+End+TBI) seems to be associated with decreased TRM and better DFS, but a multivariate analysis with a higher number of patients is needed.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 1951-1951
Author(s):  
Xiaohua Chen ◽  
Mark Vander Lugt ◽  
Memphis J Hill ◽  
Paul Szabolcs

Abstract Introduction: Compared to peripheral blood, umbilical cord blood (UCB) contains relatively higher frequencies of regulatory T cells (Tregs) with a distinct CD4+CD25bright subset. This may partially explain the less frequent and less severe acute graft-versus-host disease (aGvHD) seen in UCB transplantation (UCBT), in particular when comparing to similarly HLA-matched or mismatched living donor recipients. Treg reconstitution after UCBT is far less understood compared to living donor blood and marrow transplantation. It may also influence GvHD occurrence. Therefore, we set out to longitudinally examine the regeneration of Treg subsets and their kinetics that is impacted by proliferation and apoptosis in parallel. Tregs were defined as T cells expressing CD4+CD25brightCD127lowFoxp3+ phenotypes. Their reconstitution was examined in parallel with CD3+T cells, conventional CD4+ T cells (CD4+Tcon), sjTREC and TCRVβ repertoire complexity score. Treg reconstitution in patients with or without aGvHD was also evaluated. Methods: Twenty pediatric patients (age range from 6m to 15y) with non-malignant diseases were transplanted and studied under an IRB approved protocol with low distant Campath+Flu/Mel/Thiotepa based reduced intensity conditioning regimen (RIC) (NCT01852370). Treg subsets were examined based on combinatorial expression of CD4, CD25, CD127, Foxp3, Helios, CD45RO, CD45RA, CD62L. Proliferation activity was determined by Ki67 antigen expression. Gating strategies are shown in Fig 1. Resting/activated Tregs were defined according to Sakaguchi publication (Immunity. 2009;30:899-911). Blood samples were collected pre-UCBT, on day 100 (D+100), at 6, 9 months, and 1 year post-UCBT. For each subset in each patient, the "reconstitution rate" (RR) was determined to represent recovery status of each population, and to normalize variations among individuals and different subsets. It was calculated as a ratio of given parameter at a specific time point post-UCBT, compared to same parameter measured pre-UCBT. Results and Discussion: Treg recovery compared to other T cells. After 100 days post-RIC-UCBT, the absolute # of Tregs in those patients without aGvHD recovered to 58% pre-UCBT (0.58 RR), which was comparable to TCRb repertoires regeneration (0.8 RR). However, Treg reconstitution was faster than the recovery rate in total CD3+ T cells (0.17 RR, p=0.05), CD4+Tcon (0.22 RR, p=0.6), CD8+ Tcon (0.18 RR, p=0.3) and sjTREC (0 RR, p=0.006). Tregs co-expressing central memory phenotype (CD45RO+CD62L+) had faster recovery rates (1.0 RR, p=0.001)) than naïve subsets (0.02RR). These findings point to rapid Treg recovery post-RIC-UCBT. Treg recovery and aGvHD. At D+100, the absolute number of Tregs in patients with aGvHD, was significantly lower (Fig3a) explained by fewer of them entering the cell cycle (lower abs# of Ki67+Treg/ul, Fig3c), while there was no difference in CD4+Tcon values whether or not aGvHD occurred (Fig3b, d). This leads to an overall decreased ratio of #Treg/#CD4+Tcon and #Ki67+Treg/#Ki67+CD4+Tcon. At D+100, those with aGvHD had fewer Tregs in circulation (#/ul) displaying the central memory phenotype or Helios (Fig4). These findings point to impaired Treg homeostasis in patients with aGvHD primarily due to lower rates of proliferation, since apoptosis was not increase as measured by activated Casp3 expression. Reduced Treg numbers in those with aGvHD is likely not the consequence of poor thymopoiesis at D+100, since sjTREC production post-UCBT were similarly absent in both groups. Alternatively, it reflects differences in homeostatic expansion of the infused Treg pool. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document